Search Results

0 results for ''Boehringer Ingelheim''

You can use to get even better search results
Carrano v. Boehringer Ingelheim Corp.
Publication Date: 2024-09-09
Practice Area: Products Liability
Industry: Pharmaceuticals
Court: Connecticut Superior Court, Waterbury J.D., Complex Litigation Docket
Judge: Judge Pierson
Attorneys:
For plaintiff:
For defendant:
Case number: CV-23-6075772

Court Has Specific Jurisdiction Over All Nonresident Defendants in Product Liability Action

September 04, 2024 | Law.com

Critical Mass With Law.com's Amanda Bronstad: Delaware's Highest Court Takes Up Zantac Expert Appeal, Will Convicted Tom Girardi Go to Prison?

The Delaware Supreme Court has agreed to take up an appeal of a May 31 ruling that allowed 10 plaintiffs' experts into thousands of Zantac lawsuits.
7 minute read
September 04, 2024 | Connecticut Law Tribune

Lawsuit Linking Zantac to Cancer Diagnoses Survives Fight Over Jurisdiction

Waterbury Superior Court Judge W. Glen Pierson ruled that defendants, having registered to do business in Connecticut, consented to the jurisdiction of the state's courts.
4 minute read
UrthTech LLC v. GOJO Indus. Inc.
Publication Date: 2024-09-04
Practice Area: Discovery
Industry:
Court: U.S. District Court for the Southern District of New York, U.S. - SDNY
Judge: Magistrate Judge Katherine H. Parker
Attorneys:
For plaintiff:
For defendant:
Case number: 1:24-MC-00311

Motion to Compel Production Denied; Extrajudicial Communication Not Privileged

Bacher v. Boehringer Ingelheim Pharm. Inc.
Publication Date: 2024-08-05
Practice Area: Civil Procedure | Class Actions | Personal Injury
Industry: Pharmaceuticals
Court: U.S. Court of Appeals for Second Circuit
Judge: Justice Calabresi
Attorneys:
For plaintiff:
For defendant:
Case number: 23-877

Court Finds Defendants Failed to Prove Federal Jurisdiction and Affirms Remand of Personal Injury Lawsuits

Bacher v. Boehringer Ingelheim Pharms. Inc.
Publication Date: 2024-07-31
Practice Area: Civil Procedure | Personal Injury
Industry: Pharmaceuticals
Court: U.S. Court of Appeals for the Second Circuit
Judge: Circuit Judge Guido Calabresi
Attorneys:
For plaintiff: For Plaintiffs-Appellees: Robert A. Izard, Craig A. Raabe, Izard, Kindall & Raabe, LLP, West Hartford, CT, on the brief, John A. Bruegger, Parafinczuk Wolf, P.A., Boca Raton, FL.
For defendant: For Defendants-Appellants: Anand Agneshwar, Arnold & Porter Kaye Scholer LLP, New York, NY; Joseph W. Martini, Spears Manning & Martini LLC, Southport, CT; Patrick M. Fahey, Jamie A. Welsh, Shipman & Goodwin LLP, Hartford, CT; Lindsey B. Cohan, Dechert LLP, Austin, TX; Robert Reginald Simpson, Lauren R. Greenspoon, Shook, Hardy & Bacon LLP, Hartford, CT; James I. Glasser, James O. Craven, Wiggin and Dana LLP, New Haven, CT, on the brief, Daniel S. Pariser, Arnold & Porter Kaye Scholer LLP, Washington, D.C.
Case number: 23-877

State Suits' Consolidation Did Not Trigger Jurisdiction Under CAFA 'Mass Action' Provision

July 29, 2024 | Connecticut Law Tribune

Hundreds of Plaintiffs Deploy Litigation Strategy in Zantac Suits

"Juries can be fickle, and if you have to try nine cases nine times, you may get nine different results," Peter Bowman, a personal injury lawyer for BBB Attorneys, said.
3 minute read
Raviv v. Boehringer Ingelheim Pharm., Inc.
Publication Date: 2024-07-22
Practice Area: Products Liability
Industry: Pharmaceuticals
Court: Connecticut Superior Court, Hartford J.D. at Hartford
Judge: Judge Farley
Attorneys:
For plaintiff:
For defendant:
Case number: CV-17-6082895

Complaint About Anticoagulant Medication Dismissed

July 17, 2024 | Law.com

Critical Mass With Law.com's Amanda Bronstad: Tom Girardi's Lawyers Want Criminal Trial Moved to October, Judge Asks: Should Roundup Settlement Program Continue?

Federal public defenders for Tom Girardi have asked to delay next month's criminal trial, alleging that prosecutors "affirmatively misled" them about the scope of the case
7 minute read
July 12, 2024 | Connecticut Law Tribune

Boehringer Ingelheim Pharmaceuticals Loses Challenge to Inflation Reduction Act

"We are disappointed by this ruling and what it means for biopharmaceutical innovation," the company said. "Boehringer Ingelheim shares the goal of ensuring our medicines are affordable and available to people who need them. However, we remain concerned about the detrimental and limiting effects the IRA and its 'negotiation' program will have on the future of innovation for the patients we serve."
3 minute read

Resources

  • Why Are So Many Law Firms Suddenly Embracing Digital Transformation?

    Brought to you by AllRize

    Download Now

  • 2025 State Legislative Sessions

    Brought to you by LexisNexis®

    Download Now

  • Retention & Online Reputation for Law Firms: 2025 Guide

    Brought to you by Amazing Workplace, Inc.

    Download Now

  • Europe's Escalating Regulatory Framework: Mapping Efforts to Mitigate Supply Chain Risks

    Brought to you by LRN

    Download Now